PathologyAtlas
Waldenström macroglobulinemia †
¥¹¥¦¥§¡¼¥Ç¥ó¤ÎÆâ²Ê°åJan Gösta Waldenström (1906-1996) ¤Ë¤è¤ê1944ǯÊó¹ð¤µ¤ì¤¿¡£*1
¤Þ¤ì¤Ê¥ê¥ó¥Ñ·Á¼ÁºÙ˦À¼ðáç¤Î°ì·¿¤Ç, BºÙ˦·¿¤Î¼ðáçºÙ˦¤¬¹ü¿ñ, ¥ê¥ó¥ÑÀá¤Ë¿»½áÁý¿£¤·IgM¤ò»ºÀ¸¤¹¤ë¡£
¥ê¥ó¥Ñ¼ð¤È¹ü¿ñ¼ð¤Î¥Ï¥¤¥Ö¥ê¥Ã¥ÉÀ¼Á¤ò¤â¤Ä¼À´µ¡£ÃËÀ¤Ë¿¤¯ÃæÇ¯¤«¤é¹âÎð¼Ô¤Ëȯ¾É¤¹¤ë¡£Ä̾ï¤ÏÀøºßÀȯ¾É¤ÇÉÏ·ì, ½Ð·ì·¹¸þ(»õÆù,É¡½Ð·ì,ÈéÉæÅÀ¾õ½Ð·ì¤Ê¤É), ¿´·ì´É¾ã³²¤Ê¤É¤Î¾É¾õ¤¬¸«¤é¤ì, ¥ê¥ó¥Ñ¼ð, ´Î磼ð¤òǧ¤á¤ë¡£
¹ü¿ñ¼ð¤Î¤è¤¦¤Ê¹üÍ»²òÉÂÊѤϤߤé¤ì¤Ê¤¤¡£
monoclonal IgM paraproteinemia¤Î¸ºß¤¬Waldenström macroglobulinemia(WM)¤Îhallmark¤Ç¤¢¤ë¤¬Æ±ÍͤËmonoclonal IgM¤Îǧ¤á¤é¤ì¤ë°À¥ê¥ó¥Ñ¼ð, CLL¤È¤Î´ÕÊ̤¬º¤Æñ¤Ê¤³¤È¤¬¤¢¤ë¡£
2008ǯWHO blue book*2¤Ç¤Ïlymphoplasmacytic lymphoma(LPL)¤ÎÆÃ°Û¤Ê¥µ¥Ö¥¿¥¤¥×¤È¤·¤ÆWM¤ÏÄêµÁ¤µ¤ì, LPL¤Î¤¦¤Á¹ü¿ñÉÂÊѤ¬Â¸ºß¤·, IgM monoclonal gammopathy¤ò¤¤¿¤¹¼À´µ¤Ç,IgM¤ÎÇ»Å٤ˤè¤é¤Ê¤¤*3¤È¤Ê¤Ã¤Æ¤¤¤ë¡£
WM¤ÎÉÂÍý †
¹ü¿ñÉÂÊѤϤۤÜÁ´¾ÉÎã¤Ë¸ºß¤¹¤ë¡£WM¤Î¹ü¿ñ½ê¸«¤Ï¿ÍÍheterogenous¤Ç¤¢¤ë*4¡£
WM/LPL¤Ç¤ÏÀ®½ÏB¥ê¥ó¥Ñµå¤«¤é·Á¼ÁºÙ˦¤Þ¤Ç¤ÎºÙ˦½Ð¸½¤ò¸«¤ë¡£¤Û¤ÜÁ´Îã¤Ë¥ê¥ó¥Ñµå,·Á¼ÁºÙ˦, ·Á¼ÁºÙ˦ÍÍ¥ê¥ó¥Ñµåplasmacytoid lymphocyte¤ÎÁý¿¤¬Ç§¤á¤é¤ì¤ë¡£
- ·Á¼ÁºÙ˦ÍÍ¥ê¥ó¥Ñµå¤ÎÁý²Ã¤¹¤ë¾ÉÎã¤Ç¤ÏIgM paraprotein¤Ï¾¯¤Ê¤¯WM¤Îŵ·¿Åª¤Ê¾É¾õ¤ÏÄ褵¤Ê¤¤·¹¸þ¤Ë¤¢¤ë¡£
- ¤·¤Ð¤·¤Ðmast cell,ÁÈ¿¥µå¤ÎÁý²Ã¤òȼ¤¦¡£º®ºß¤¹¤ëmast cell¤ÎÁý²Ã¤Ïtryptase¤ÎÌȱÖÀ÷¿§¤Ç³Îǧ¤Ç¤¤ë¡£C-kitÀ÷¿§¤Ç¤â²Ä¡£ASD-GiemsaÀ÷¿§¤Ê¤éÌÈÀ÷¤·¤Ê¤¯¤Æ¤â¤¹¤°Æ±Äê¤Ç¤¤Þ¤¹¡£À÷¿§¤¬¤¦¤Þ¤¯¤¤¤Ã¤Æ¤¤¤ë»ØÉ¸¤Ë¤â¤Ê¤ë¡£
- ºÙ˦¼ÁÆâÉõÆþÂÎ, ³ËÆâÉõÆþÂΤȤ¯¤ËDutcher body¤¬¤·¤Ð¤·¤Ðǧ¤á¤é¤ì¤ë¡£
- ¤Þ¤ì¤ËPASÍÛÀ, signet-ring cell¤¬½Ð¸½¤¹¤ëWM¾ÉÎ㤬¤¢¤ë¡£
- ¿ñÆâÉÂÊÑʬÉÛ¤Ïnodular(pratrabecular¤ª¤è¤Ónon-paratrabecular), interstitial, mixed nodular and interstitial, diffuse solid lesion¤ò¤È¤ë¡£
- reticlin fibrosis¤Ï¶É½êÉÂÊѤˤȤɤޤ롣
- smearƱÍ͹ü¿ñÀ¸¸¡ÁÈ¿¥¤Ç¤âlymphplasmacytic cell¤ÎÁý²Ã¤¬¸²Ãø¤Çimmunoblast¤âÁý²Ã¤¹¤ë¤³¤È¤¬¤¢¤ë¡£amyloid¤ÎÄÀÃ夬À¸¸¡ÁÈ¿¥¤Ëǧ¤á¤é¤ì¤ë¤³¤È¤¬¤¢¤ë¡£
¹ü¿ñÁÈ¿¥¡¦ºÙ˦ɸËÜ †
¹ü¿ñ¥¹¥á¥¢É¸ËܤǤ¹¡£¤Í¤Ã¤È¤ê¤·¤¿·ìÀ¶À®Ê¬¤¬¤è¤¯¤ï¤«¤ê¤Þ¤¹¡£¡Öhyperviscosity¡×¤Î¾õÂÖ= ²áÇ´ãÇ(¤Í¤ó¤Á¤å¤¦-¤ÈÆÉ¤à¤é¤·¤¤)¾É¾õ; hyperviscosity¤ÎÀµ¤·¤¤Ìõ¤Ï²áÇ´Å٤Τۤ¦¤¬¤è¤¤¤È»×¤¦.
ÀÖ·ìµå¤¬º÷¾õ¤ËÏ¢¤Ê¤ëÏ¢Á¬·ÁÀ®rouleaux¤¬ÌÀÎÆ¤Ç¤¹¡£
bone marrow clot section¡ÊMay-GiemsaÀ÷¿§)ɸËÜ
metachromatic basophilic granules¤ò¤â¤Ämast cell¤¬Â¿¿ô½Ð¸½¤¹¤ë
plasmacytoid lymphocyte
WM¼ðáçºÙ˦ †
WM¼ðáçºÙ˦¤ÎͳÍè
WM¤ÎBºÙ˦¥µ¥Ö¥»¥Ã¥È¤Ï¹ü¿ñ,ç£Â¡ÊÕ±ïÂÓ, ¥ê¥ó¥ÑÀá, Ëö¾¿·ì¤Ë¸ºß¤¹¤ë¡£WM¼ðáçBºÙ˦¤ÎͳÍè¤Ë¤Ä¤¤¤Æ¤ÏŤ¯µÄÏÀ¤µ¤ì¤Æ¤¤¿¡£*5
- WM¤Îlymphoplasmacytic cell¤Ïpost germinal center B cellͳÍè¤Î¥¯¥í¡¼¥ó
- WM¤Î¼ðáçºÙ˦¤Înormal counter part¤ÏIgM+ and/or IgM+, IgD+ memory B cell
- Ig heavy chain °äÅÁ»ÒºÂ(14q23)¤Îtranslocation¤Ïǧ¤á¤é¤ì¤Ê¤¤
- postswitch clonotypic Ig (IgG, IgA)¤Ï¸ºß¤»¤º, isotype switch¤Ïµ¯¤³¤Ã¤Æ¤¤¤Ê¤¤¡£
- WM¤Ç¤ÏIgH variable region(VH)¤Ë¤Ïsomatic mutation¤¬³Îǧ¤µ¤ì¤ë¡£
- ¤Û¤È¤ó¤É¤ÎWH¼ðáçBºÙ˦¤Ç¤ÏVH3/JH4 gene family¤¬»È¤ï¤ì, hypermutated¤Ç¤¢¤ë¡£intraclonal heterogeneity¤Ï·çÇ¡¤·¤Æ¤¤¤ë¡£
- WM¼ðáçBºÙ˦¤Ç¤ÏÀµ¾ï¤Îclass switch recombination¤Îµ¡Ç½¤ÏÊݤ¿¤ì¤Æ¤¤¤ë¤¬, switching process¤Î³«»Ï¤Ë°Û¾ï¤ò¤¤¿¤·¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£
WM¼ðáçºÙ˦¤ÎÌȱÖÀ÷¿§*6
- pan B-cell marker, CD19, CD20, CD22¤¬ÍÛÀ¤Ë¤Ê¤ë¡£
- cytoplasmic Ig(cIg), FMC7, bcl-2, PAX5, CD38, CD79a¤ÏÍÛÀ¡£
- CD10, CD23¤Ï¤Û¤ÜÁ´Îã¤Ç±¢À
- CD5¤Ï5¡Á20%¤ÇÍÛÀ¤È¤Ê¤ë¡£
¾ÉÎã¤Ë¤è¤ëvariation¤Ï¸«¤é¤ì¤ë¤¬, ¿·µ¬¿ÇÃÇ´ð½à*7*8¤Ç¤Ï
- monoclonal surface Ig (sIg)ÍÛÀ¡£(kappa/lambda= 5:1)
- CD19+, CD20+, CD5-, CD10-, CD23-
- CD5+¤ÇWM¤òÈÝÄꤹ¤ë¤³¤È¤Ë¤Ï¤Ê¤é¤Ê¤¤¡£
- CD23+¤È¤Ê¤ë¾ÉÎ㤬Êó¹ð¤Ë¤è¤ê¸ºß¤¹¤ë¡£(35%, 61%¤Ê¤É)
WM¼ðáçºÙ˦¤Î°äÅÁ»Ò°Û¾ï †
MYD88 mutation¤ÈWaldenstroem macroglobulinemia †
Waldenström macroglobulinemia¤Î´µ¼Ô¤µ¤ó¤Ë¤ÏMYD88 L265P¤Îsomatic mutation¤¬¹âΨ¤Ëǧ¤á¤é¤ì¤ë¤³¤È¤¬¹ü¿ñlymphoplasmacytic cell¤Îwhole genome sequenceʬÀϤˤè¤êȯ¸«¤µ¤ì¤¿¡£*9
- WM¤È¿ÇÃǤµ¤ì¤¿LPL 30Îã¤ÎËö¾¿·ì, ¹ü¿ñ¤«¤é¥½¡¼¥È¤·¤¿CD19ºÙ˦¤ò¤â¤Á¤¤¤¿Á´¥²¥Î¥à¥·¡¼¥¯¥¨¥ó¥¹¤Ç27/30Îã¤ËMYD88°äÅÁ»ÒL265PÊѰۤ¬¸¡½Ð¤µ¤ì¤¿¡£Sanger¥·¡¼¥¯¥¨¥ó¥¹¤ÇWM 49/54Îã(91%), IgMÈóʬÈçÀLPL 3/3Îã(100%)¤¬MYD88L265PÊѰÛÍÛÀ¤Ç¤¢¤Ã¤¿¡£°ìÊýIgM-MGUS¤Ç¤Ï2/21Îã(10¡ó¡Ë¤ÈÄãÉÑÅ٤Ǥ¢¤Ã¤¿¡£*10
- MYD88¤ÎÆóÎ̲½Á˳²ºÞ¤È¤È¤â¤ËWMºÙ˦¤òÇÝÍܤ¹¤ë¤È, MYD88¥·¥°¥Ê¥ë¤¬ÍÞÀ©¤µ¤ì, I¦ÊB¦Á, NF-¦ÊBp65¤Î¤ê¤ó»À²½¤ÈNF-¦ÊB¤Î³ËÀ÷¿§¤¬ÃøÌÀ¤Ë¸º¾¯¤·¤¿¡£Æ±Íͤʷë²Ì¤ÏIRAK1/4¥¥Ê¡¼¥¼Á˳²ºÞ¤òMYD88ÊѰÛÍÛÀMWºÙ˦¤Ëź²Ã¤·¤Æ¤âǧ¤á¤é¤ì¤ë¡£°ìÊýÌîÀ¸·¿MYD88¤ÎWMºÙ˦¤Ç¤ÏMYD88¥·¥°¥Ê¥ëÍÞÀ©¤Ë¤è¤ë, ¤³¤ì¤é¤ÎÊѲ½¤Ï¸«¤é¤ì¤Ê¤«¤Ã¤¿¡£*10
- PCR-RFLP¤Ë¤è¤ë²òÀϤǤÏWM¾ÉÎã 18/27Îã¡Ê67¡ó¡Ë¤ËL265PÊѰۤ¬Ç§¤á¤é¤ì¤¿¡£
- MYD88L265PÊѰ۸¡½Ð¤Ï, WM¤ÈIgM¤ò»ºÀ¸¤¹¤ë¾¤Î¥ê¥ó¥Ñ·Ï¼ðáç¤Î´ÕÊÌ¿ÇÃǤËÍÍѤȹͤ¨¤é¤ì¤ë¡£
WM¤Î¤½¤Î¾¤Î°äÅÁ»ÒÊÑ°Û †
WM30¾ÉÎã¤ÎÁ´¥²¥Î¥à¥·¡¼¥¯¥¨¥ó¥¹¤Ë¤ª¤¤¤Æ10%°Ê¾å¤Î¾ÉÎã¤ÇÊѰۤòǧ¤á¤¿°äÅÁ»Ò¤ÏMYD88°äÅÁ»Ò(90%)¤Î¤Û¤«¤Ë*11
- CXCR4°äÅÁ»Ò 27%
- ARID1A°äÅÁ»Ò 17% ¤Ç¤¢¤Ã¤¿¡£
WM¤ÎCXCR4°äÅÁ»ÒÊѰÛ
- CXCR4°äÅÁ»Ò¤Îgermline°Û¾ï¤Ë¤è¤êµ¯¤³¤ë WHIM( Warts, hypoganmaglobulinemia, infections and myelocathexis)¾É¸õ·²¤Ë¤ª¤¤¤ÆÊó¹ð¤µ¤ì¤Æ¤¤¤ënonsenseÊѰۤäframeshift(FM)ÊѰۤËÎà»÷¤·¤Æ¤¤¤¿¡£*11
- WHIM¤Ç¤Î°äÅÁ»Ò°Û¾ï¤Ï¤Û¤È¤ó¤É¤¬nonsenseÊѰÛ(R334X, S338X)¤Çframe shiftÊѰۤϾ¯¿ô¡£
- WM¤Ç¤Ï, 51/ 175Îã(29.1%)¤ËCXCR4ÊѰۤ¬Ç§¤á¤é¤ì, nonsenseÊѰÛ25Îã(49%), frameshiftÊѰۤ¬26Îã(51%)¤Ç¤¢¤Ã¤¿*10
- CXCR4°äÅÁ»ÒÊѰۤΤ¢¤ëWM¾ÉÎã¤Ë¤ÏÁ´Îã¤ËMYD88°äÅÁ»ÒÊѰۤ¬Ç§¤á¤é¤ì¤¿
- CXCR4°äÅÁ»Ò¤ÎnonsenseÊѰۤϲáÇ´ãǾɸõ·²¤Î¤è¤¦¤ÊµÞ®¤Ë¿Ê¹Ô¤¹¤ë¾ÉÎã¤Ëǧ¤á¤é¤ì¤¿¤¬À¸Ì¿Í½¸å¤Ë¤Ï´Ø·¸¤·¤Ê¤«¤Ã¤¿¡£
- CXCR4°äÅÁ»ÒnonsenseÊѰۤÈMYD88L265PÊѰۤȤ¬Î¾Êýǧ¤á¤é¤ì¤ë¾ÉÎã¤Ï¹ü¿ñ¿»½á¤Î¼ðáçÎ̤¬Â¿¤¯IgM¤¬¹âÃͤǤ¢¤Ã¤¿¡£
- MYD88L265PÊѰۤΤʤ¤¾ÉÎã¤Ï, ÊѰÛÍÛÀÎã¤ÈÈæ¤Ùȯ¾ÉǯÎ𤬹⤯, ¹ü¿ñ¿»½á¤Ï¾¯¤Ê¤«¤Ã¤¿¤¬À¸Â¸´ü´Ö¤Ïû¤«¤Ã¤¿¡£*10
WM¤Î¼£ÎÅ †
¾É¾õ¤Î¤¢¤ë´µ¼Ô¤µ¤ó¤Ë¼£ÎŤò³«»Ï¤¹¤ë¡£·ìÀ¶IgMÁý²Ã¤Î¤ß¤Ç¤Ï¼£ÎÅÂоݤȤ·¤Ê¤¤¡£*12
- HbÇ»ÅÙ¡ã10g/dl, platelet count¡ã10Ëü/ml
- Ãø¤·¤¤adenopathy, ¡´ï¼ðÂç, hyperviscosity¤Î¾É¾õ¤¢¤ê, ½Å¾Éneuropathy, amyloidosis, cryogloblinemia, cold agglutinin disease, ¼À´µ¤Îtransformation¤¬ÌÀÎÆ¤Ê¤È¤
- IgM paraprotein ¡ä5g/dl¤Ë¤Ê¤ë¤Èhyperviscosity ¤Î´í¸±¤¬½Ð¸½¤¹¤ë¡£
chemotherapy
- Âè°ìÁªÂò¤Ï¥¢¥ë¥¥ë²½ºÞ(chlorambucil, cyclophosphamide, melphalan), ¥×¥ê¥ó¥¢¥Ê¥í¥°(cladribine, fludarabine)¤ª¤è¤Ómonoclonal¹³ÂÎ(rituximab)
- ·ìÞù¸ò´¹(1-1.5L)¤Ïacute hyperviscosity¤ËŬ±þ¤È¤Ê¤ë¡£
- ¥×¥ê¥ó¥¢¥Ê¥í¥°¤¢¤ë¤¤¤Ïrituximab¤¬initial combination therapy¤È¤Ê¤ë¡£
- chrolambucil¤ÏÂè°ìÁªÂòÌô¤È¤µ¤ì¤Æ¤¤¤¿¡£response rate¤Ï31-92%¤È¤µ¤Þ¤¶¤Þ¤ÊÊó¹ð¤¬¤¢¤ë¡£
- cladribine. response rate: 44-90%
- fludarabine. response rate: 38-100%
- rituximab. response rate: 20-50%
- CD16(Fc¦ÃR·A)¤Îpolymorphism¤Ïrituximab¤Î¸ú²Ì¤Ë±Æ¶Á¤ò¤¢¤¿¤¨¤ë¡£
- thalidomide¤ÎWM¤Ø¤Î¸ú²Ì¤ÏñºÞ, ¿ºÞ¤È¤â¤Ë¸ÂÄêŪ¤Ç¤¢¤ë
- High dose chemotherapy¤Èautologous stem cell transplantation¤â»î¤ß¤é¤ì¤Æ¤¤¤ë¡£
WM¤ËÂФ¹¤ëÆÃ¸úÌô¤È¤¤¤¦¤â¤Î¤Ï¸½»þÅÀ¤Ç¤Ï¤Ê¤¯, ¸Ä¡¹¤Î´µ¼Ô¤µ¤ó¤Î¾õ¶·¤Ë±þ¤¸¤ÆÁªÂò¤¹¤ë¡£¥¢¥ë¥¥ë²½ºÞ¤Ë¤Ä¤¤¤Æ¤Ïautologous transplantation¤ò»î¤ß¤è¤¦¤È¤¹¤ë´µ¼Ô¤µ¤ó¤Ç¤ÏÁªÂò¤·¤Ê¤¤¤³¤È¤ò¿ä¾©¤¹¤ë¡£°Ü¿¢¤Î¸úǽ¤Ë¤Ä¤¤¤Æ¤Ï°ú¤Â³¤¸¡Æ¤¤òÍפ¹¤ë¡£*12
WM/LPL¤Î¼£ÎÅ up to date †
LPL/WM¤Î¼£ÎÅ¡¡up to date --->¸×¥ÎÌçɱ¡·ì±ÕÆâ²Ê¡¡°ËƦÄÅÀèÀ¸¤Î¹Ö±é¤Ø¡ÊÂè6²ólymphomania¤ÎÉÂÍý¿ÇÃÇ¥³¡¼¥¹¤è¤ê)
¸¶È¯À¥Þ¥¯¥í¥°¥í¥Ö¥ê¥ó·ì¾É¤Ø¤Î¥¤¥Ö¥ë¥Á¥Ë¥ÖÎÅË¡
Ibrutinib: BTK inhibitor(¥Ö¥ë¥È¥ó·¿¥Á¥í¥·¥ó¥¥Ê¡¼¥¼¡ÊBTK¡ËÁ˳²ºÞ)--¡äibrutinib ¤ÎÀâÌÀ